In the NAFLD vs. control group, significant dysregulation was observed in numerous pathways, such as ECM receptor interactions, higher amebiasis prevalence, and the complex role of p53 in disease progression [40–42]. This evidence concerns the gene TP53 and metabolic dysfunction-associated steatotic liver disease.